PMCB

PharmaCyte Biotech, Inc. (PMCB) - 10-Q Summary

Business Context and Reporting Period

Company: PharmaCyte Biotech, Inc.
Filing Type: Form 10-Q (Unaudited)
Period: Three and six months ended October 31, 2025
Business Overview: A biotechnology company developing cellular therapies for cancer using proprietary "Cell-in-a-Box" technology. The primary product candidate, CypCaps, targets locally advanced, inoperable pancreatic cancer (LAPC). The company is currently under an FDA clinical hold placed in October 2020 and is conducting preclinical studies to address regulatory requirements. A reconstituted Board and Business Review Committee are evaluating the company's strategy and its relationship with technology licensor SG Austria.

Key Financial Metrics

Operating Expenses (Six Months): Total operating expenses were $2,224,356, comprising $236,242 in R&D and $1,988,114 in General and Administrative (G&A) costs.

Material Changes vs. Prior Period

• Net Income/Loss Volatility: The company reported a net loss of $15.8 million for the six months ended Oct 31, 2025, compared to a net income of $21.95 million for the same period in 2024. This reversal is primarily driven by non-cash fair value adjustments on financial instruments rather than operational performance.
• Warrant Liability Fair Value: A significant non-cash loss of $10.23 million was recorded due to the change in fair value of warrant liabilities (Series B and Settlement Warrants), compared to a gain of $3.91 million in the prior year period.
• Investment Fair Value: The company recognized a loss of $5.21 million on the change in fair value of its investment in Q/C Technologies, Inc. (QCLS) preferred stock, offset partially by a $2.09 million gain on a new related-party investment in QCLS Series H preferred stock.
• Capital Structure: In August 2025, the company completed a Series C private placement, issuing 7,000 shares of convertible preferred stock and warrants for gross proceeds of $7 million. This resulted in the recognition of $1.23 million in issuance costs and a $215,000 loss on issuance.
• Legal Settlement: The company settled a breach of contract claim with H.C. Wainwright & Co., LLC for $1.55 million (paid in cash and warrants), reducing accrued legal settlement liabilities from $2.02 million to $175,000.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity: Management expects current cash resources (approximately $21 million including subsequent Femasys note maturity) to be sufficient for at least the next 12 months. However, additional capital will be required to complete clinical trials.
• Regulatory Status: The FDA clinical hold on the LAPC IND remains in effect. The company is actively addressing FDA requests, including stability studies and biocompatibility assessments. Management is seeking to forego a large animal study, arguing that existing human clinical trial data is sufficient.
• Nasdaq Compliance: On December 1, 2025, the company received notice of non-compliance with Nasdaq's Minimum Bid Price Rule ($1.00 per share). The company has 180 days (until June 1, 2026) to regain compliance, potentially via a reverse stock split.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient segregation of duties for the CFO and insufficient management review controls.
• Unusual Items: Results are heavily influenced by fair value accounting for complex financial instruments (warrants, convertible notes, and preferred stock investments). The "Gain on related party investment" of $2.09 million arose because the fair value of the QCLS Series H investment exceeded the purchase price at issuance.

Investor Verification Checklist

• FDA Clinical Hold Resolution: Verify the status of the FDA's review of the company's response to the clinical hold and the likelihood of lifting the hold without further large animal studies.
• SG Austria Relationship: Confirm the outcome of the Business Review Committee's evaluation of the relationship with SG Austria, given that all licensed patents have expired and know-how resides with the licensor.
• Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement or confirm if a reverse stock split is approved by shareholders.
• Capital Requirements: Assess the timeline and cost to complete the LAPC clinical trial versus current cash reserves to determine the need for dilutive financing.
• Internal Control Remediation: Review the company's plan to remediate the identified material weaknesses in internal controls over financial reporting.